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Debate continues over the effectiveness of screening by mammography in women below age 50. We report here on results of
screening in the first 10 years of a randomised trial to study the effect on breast cancer mortality of invitation to annual
mammography from age 40 to 41 compared to first invitation to the 3-yearly UK national programme at age 50–52. The trial is taking
place in 23 NHS breast screening centres. Between 1991 and 1997, 160921 women were randomised in the ratio 1:2 to
intervention and control arms. Screening is by two views at first screen and single view subsequently; data on screening up to and
including round five are now complete. Uptake of invitation to screening is between 68 and 70% at all but the latest screening rounds.
Rates of referral for assessment are 4.6% at first screen and 3.4% at subsequent screens. Invasive cancer detection rates are 0.09% at
first screen, and similar at rescreens until the sixth and later screens. There is little evidence of regular mammography in the trial
control arm. The setting of this trial within the NHS breast screening programme should ensure applicability of results to a national
programme.
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The effectiveness of screening for breast cancer by mammography
in women below age 50 remains unproven, and is the subject of
much debate. While evidence from randomised controlled trials
(RCTs) increasingly suggests the existence of some benefit from
screening in women below age 50 at trial entry, these trials were
not specifically designed to address this question, and the extent to
which the observed benefit results from screening in these women
after they reach age 50 remains unclear. Analyses of some trials by
age at diagnosis suggest a benefit from screening episodes under
age 50, but such analyses reduce the comparability of the
intervention and control arms and hence the reliability of the
results.
The majority of population-based screening programmes that
have been introduced offer screening to women from age 50,
although in Sweden some counties invite women from age 40
(Shapiro et al, 1998). In the UK, the effectiveness of screening
below age 50 was identified as one of the areas where further
research was needed, at the time the national screening
programme was introduced (Forrest, 1986). The Age Trial
(International Standard Randomised Controlled Trial Number –
ISRCTN: 24647151) was designed specifically to study the question
of the benefit of starting screening from age 40. The unique
features of this trial are annual mammography (frequently
recommended for this age group) and freedom from bias due to
screening episodes over age 50.
MATERIALS AND METHODS
The design of the trial has been described in detail elsewhere
(Moss, 1999). The aim was to randomise 195000 women aged 40–
41 in a ratio of 1:2 to an intervention arm offered annual
screening by mammography, and a control arm with no
intervention. Women in the intervention arm are invited for
screening until the calendar year of their 48th birthday; after age
50, both they and women in the control arm are eligible for three-
yearly invitation as part of the NHS Breast Screening Programme
(NHSBSP), and will receive their first invitation between age 50
and 52 years. Screening in the trial is by two-view mammography
at the first screen, with single view thereafter unless otherwise
indicated. All women, including nonattenders, are reinvited
annually unless they ask not to be contacted again. Women who
move to areas not covered by the trial are not reinvited for
screening as part of the trial, but are able to self-refer to either their
previous or their nearest participating screening centre.
The sample size of the trial was calculated to give an 80%
probability of demonstrating as statistically significant a reduction
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yof 20% in breast cancer mortality at 10 years of follow-up at the 5%
significance level, using a one-tailed test, on an ‘intention-to-treat’
basis. This was based on an estimated cumulative breast cancer
mortality of 3.3 per 1000 women in the control group among an
initially disease-free population, using the method described by
Moss et al (1987).
The trial began in 1991, and includes 23 established NHSBSP
centres(Table 1). Randomisation is individual, stratified by GP
practice. Women were identified from the (then) Family Health
Services Authority (FHSA) computerised register, as is the case for
the national screening programme. Women were selected by year
of birth to include those who would be 40 or 41 when offered their
first invitation or who would become 40 in the calendar year of
their first invitation. Prior Notification Lists (PNLs) were
generated (before randomisation) and sent to the appropriate
GPs for checking and exclusion of women (e.g. known to be dead,
wrong age, under care for breast cancer, etc.). Owing to updating
of the date of birth information at the screening centres after
randomisation (mostly for women in the intervention arm), some
women are outside the trial age range, but are included in the
analyses.
From 1992, randomisation was carried out using software
specifically written for the FHSA computer system. Prior to this,
randomisation was carried out using numbers generated from the
coordinating centre computer for women in three early centres to
join the trial. The date of entry is equal to the date of
randomisation, except where randomisation was carried out at
the coordinating centre; for one of these centres, date of entry was
the date when randomisation lists were returned; for the other two,
it was set to a date 8 weeks (the mean interval between date of
entry and date of first invitation in centres where randomisation
was carried out by the FHSA computer system) before the date of
first invitation for women in the intervention arm. For women in
the control arm, it was set to the date of entry of those in the
intervention arm with the same or nearest date of birth in the same
general practice.
Between 1993 and 1995, difficulties were encountered in
recruiting new centres, due partly to uncertainties over funding
and partly to centres being unable to take on additional workload
while maintaining NHSBSP screening. After 1996, no further
centres were recruited; in 1999, the Data Monitoring Committee
recommended that recruitment officially cease, and this was
subsequently agreed upon by the Trial Steering Committee. A total
of 160921 women had been randomised, 53914 to the intervention
arm and 107007 to the control arm; the probability of
demonstrating a 20% breast cancer mortality reduction at 10
years of follow-up (under the same assumptions as above) is thus
reduced to 73%.
In three centres, Cumbria, Hull and Worthing, screening in the
trial ceased prematurely (after four, five and six rounds,
respectively) due to inability to manage the additional workload
with the available resources. In the primary mortality analysis,
women in these centres will be included on an ‘intention-to-treat’
basis, although analyses taking account of the length of interven-
tion may also be considered.
A woman’s first trial invitation within 6 months of entry into the
study is defined as round one. After the first invitation, a screening
round is defined as the offer of a routine trial screen in a 10–14
month period following the previous screen (or invitation to
screen). A woman may accrue more than eight screening rounds
during the trial, depending on her age in the calendar year of her
first invitation. Uptake and outcome of screening are presented by
screening rounds, with results combined for later screening rounds
as yet incomplete.
An interval cancer is defined as one diagnosed following a
negative screen (including return to routine recall following
assessment) and occurring before the next offered appointment.
Cancers in lapsed attenders are those cancers occurring in women
whose last attended screen was negative and who were diagnosed
after declining subsequent invitations to attend. Cancers in women
who have moved away from their original centre and hence no
longer invited are included as ‘lost to screening’.
Recruitment of centres to the trial took place between 1991 and
1996 (Table 1), with randomisation ending in 1997. Results in the
present paper include data up to 31st March 2002, with a mean of
8.0 years follow-up from the date of entry. Owing to incomplete
ascertainment of breast cancers in the most recent years, incidence
rates and the analysis of sensitivity of screening are based on data
up to 31st December 1999.
Woman-years for analysis of all-cause mortality are calculated
from each woman’s date of entry to date of death or 31st March
2002, whichever is earlier. Those for analyses of incidence are
calculated from the date of entry to the date of death or 31st
December 1999, whichever is earlier, and are also censored at the
date of diagnosis of breast cancer.
The sensitivity of screening at different screening rounds has
been estimated by the ‘proportional incidence’ method (Day,
1985), using age-specific incidence rates in the control arm to
calculate the expected numbers of cancers in the absence of
screening. Owing to the fact that the observed incidence in the
never-attenders is lower than that in the control arm, the expected
incidence ia in the attenders has been calculated for each round
(assuming everyone is age 40 at first screen, 41 at second screen,
etc.) as
ia ¼ð ic  ð 1   pÞinaÞ=p
where p is the the proportion of ever-attenders, ic is the age-
specific incidence rate in the control arm (based on a 3-year
moving average) and ina is the incidence rate in the nonattenders.
Owing to fluctuation due to small numbers, ina is estimated as
ic Ina/Ic, where Ina and Ic are the overall incidence rates in the
nonattenders and control arm, respectively.
The primary end point of the trial is a comparison of mortality
from breast cancer in the two arms of the trial, in women free from
breast cancer at date of entry. All women in the trial are flagged at
the National Health Service Central Register (NHSCR), which
provides information on deaths from all causes and on cancer
Table 1 Recruitment of centres to the trial
Trial centre
Date centre
joined study
Population
contributed
Cumulative
population
Guildford February ‘91 12110 12110
Edinburgh May ‘91 5659 17769
Derby June ‘92 10853 28622
Avon August ‘92 8895 37517
Manchester September ‘92 7181 44698
Stoke September ‘92 8077 52775
Epping October ‘92 6938 59713
N. Nottinghamshire November ‘92 3621 63334
Nottingham November ‘92 8353 71687
Worthing January ‘93 6506 78193
Aylesbury February ‘93 1942 80135
Bromley February ‘93 5834 85969
Hull July ‘93 9793 95762
Swindon November ‘93 4601 100363
Bradford January ‘94 14425 114788
Sheffield July ‘94 6187 120975
Warrington September ‘94 7105 128080
Wirral October ‘94 7047 135127
Cumbria November ‘94 6123 141250
North London January ‘95 4455 145705
Peterborough February ‘95 4393 150098
Newcastle November ‘95 6288 156386
Swansea January ‘96 4535 160921
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undertaken (Anderson et al, 2002), to enable an earlier analysis
based on surrogate outcome measures to be performed (Moss et al,
2005).
A radiology review is also being undertaken of all screen-
detected, interval and lapsed-attender cancers notified in the trial,
in order to identify and highlight the radiological features most
frequently missed or misinterpreted when screen reading the
mammographic films of younger women, and to identify which
features are most helpful to observe when reading mammograms
of younger women. The results of this review will be submitted for
publication at a later date. During the course of the trial, radiation
doses were collected and reviewed; the findings of this work have
been published elsewhere (Young, 2002).
‘Contamination’ with private screening in the trial’s control
population was assessed by postal questionnaires sent to a total of
3755 women in five participating centres, asking about past
mammography for both symptomatic and screening purposes.
Women were aged 42–49 years at the time of the survey.
RESULTS
Figure 1 and Table 2 show the number of women randomised by
trial arm and by individual year of age. A total of 160921 women
were randomised after checking of lists by GP’s; more than 99.9%
of women randomised have been successfully traced and flagged at
NHSCR. A total of 60 women were excluded from analyses for
reasons given in the flowchart (Figure 1).
Table 3 shows the uptake of screening at successive rounds, and
also demonstrates the loss of women to screening, with 84.3% of
women randomised to the intervention arm invited at round five.
A total of 1215 women were first invited more than 6 months after
their date of entry, and therefore were not invited in round one
according to our definition. A further 82 women were never invited
due to updates in their Health Authority information, which made
them ineligible for invitation (e.g. they were under care or had
moved away).
For routine trial screens, 94% of appointments were offered
between 10 and 14 months after the previous screen, and 56% after
12 months (72 weeks). In all, 93% of screens attended took place
at 10–14 month intervals.
Data on screening up to and including round five are now
complete, but women with the earliest dates of entry will have six
or more rounds. Women in the intervention arm have received a
mean of 6.6 routine invitations compared with a potential of 7.5 if
there had been no loss to follow-up. Uptake of invitations is
Intervention arm 
53914 
Control arm 
107007
Excluded from analysis
•   8 not traced at ONS/GRO
•  10 deceased before entry
•  5 emigrated before entry 
•   1 male 
Excluded from analysis
•  8 not traced at ONS/GRO  
• 19 deceased before entry
•   5 emigrated before entry
•  
53890  106971
Identified from HA and 
 randomised (after  
checking of PNLs) 
160921
4 male 
Figure 1 Flow diagram of the progress through the phases of the trial.
Table 2 Number of women randomised
Intervention arm Control arm
Age at entry n % n %
o38 21 o0.1 8 o0.1
38 158 0.3 285 0.3
39 16724 31.0 32841 30.7
40 26387 49.0 52141 48.7
41 10419 19.3 21597 20.2
441 181 0.3 99 0.1
Total 53890 106971
Mean age at entry 40.38 40.39
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increases with number of previous attendances; uptake is over 95%
in women who have attended at least five previous screens.
In all, 81% of women in the intervention arm have attended at
least one invitation for routine screening, and of these, 50% (41%
of the intervention arm) have attended all their invitations to
routine screening within the trial.
Screening performance
Table 4 shows the numbers and rates of referrals for assessment,
biopsies and in situ and invasive cancers detected, by screening
round. Mean age will increase with successive rounds, and the
rates analysed by age at screening are very similar to those by
screening round. Overall rates of referral for assessment are 4.6%
at first screen (first invitation) and 3.4% at subsequent screens.
Invasive cancer detection rates are 0.09% at first screen, and
similar at rescreens until the sixth and later screens. Detection
rates of in situ cancer (including microinvasive) are 0.02% at first
invitation, and increase slightly in the latest rounds. Rates of
referral, biopsy and cancer detection are raised in first screens of
previous nonresponders.
Table 5 gives the numbers of breast cancers in the control arm
and in the intervention arm by method of detection. The incidence
rate in women in the intervention arm never attending screening is
1.03 per 1000 women-years, compared with 1.32 per 1000 women-
years in the control arm. The incidence rate in the intervention
arm is 1.54 per 1000 women-years. A total of 99 invasive interval
cancers (plus five in situ) have been detected in the 12 months
following a negative screen (including return to routine recall
following assessment). A further 21 cancers (invasive and in situ)
have been detected after 12 months but before the woman had
received her next invitation. In all, 44 cancers occurred in women
who have failed to attend for later screens, and 14 in the ‘lost to
screening’ group.
Table 6 shows the numbers of observed and expected invasive
interval cancers; the sensitivity of the first screen is 73.6%, and of
subsequent screens is 54.1%. For subsequent screens, sensitivity
increases from 46.8% at screens two and three to 64.5% at screen
six or later.
All-cause mortality
Table 7 shows the mortality from all causes excluding breast
cancer, which is similar in the two arms of the trial (control: 1.29;
intervention 1.34 per 1000 women years).
Table 3 Women invited and uptake of screening (data up to 31 March
2002)
Women
screened
Screening
round
Women
invited n % % Population screened
a
1 52593 35846 68 67
2 48942 33784 69 63
3 46985 31961 68 59
4 45640 31311 69 58
5 45451 31334 69 58
6 43030 29693 69
7 37062 26061 70 Incomplete screening rounds
8 26832 18805 70
X9 8923 5917 66
aNumber of intervention arm women screened (by round) expressed as a
proportion of the number potentially available for invitation on the basis of the
amount of time elapsed since each woman entered the trial.
Table 4 Outcome of screening (data up to 31 March 2002)
No.
screened Referred
%o f
screened Biopsied
%o f
screened
In situ
cancer
detected
%o f
screened
Invasive
cancer
detected
%o f
screened
Total
cancer
detected
%o f
screened
PPV of
assessment
%
PPV of
biopsy
%
First invitation 35846 1655 4.6 93 0.26 6
a 0.02 31 0.09 37 0.10 2 40
First screening
round in previous
nonresponders
7679 511 6.7 48 0.63 3 0.04 14 0.18 17 0.22 3 35
Second routine
screening round
39912 1324 3.3 70 0.18 8 0.02 33 0.08 41 0.10 3 59
Third routine
screening round
37128 1323 3.6 77 0.21 8 0.02 34 0.09 42 0.11 3 55
Fourth routine
screening round
34082 1161 3.4 75 0.22 9
a 0.03 28 0.08 37 0.11 3 49
Fifth routine
screening round
29818 989 3.3 61 0.20 12
b 0.04 23 0.08 37
c 0.12 4 61
Subsequent
routine screening
rounds
60206 2072 3.4 166 0.28 28
d 0.05 69 0.11 98
e 0.16 5 59
PPV¼positive predictive value.
aThis value includes one microinvasive case.
bThis value includes four microinvasive cases.
cThis value includes two cases where invasive status is
not known.
dThis value includes two microinvasive cases.
eThis value includes one case where invasive status is not known.
Table 5 Breast cancers by method of detection (data up to 31
December 1999)
Intervention arm Control arm
Between randomisation and invitation 9
Never-attenders 61
Screen detected: total 229
Interval cancers
Before next invitation 125
Lapsed attenders 44
‘Lost to screening’ 14
Total 482 821
In situ and microinvasive cases included.
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Of the 3755 women sent questionnaires, 2115 (56.3%) responded
and 2041 (54.4%) were suitable for analysis. Of these, 18% reported
ever having had a mammogram for symptomatic reasons, and
8.4% reported having had a screening mammogram, 3.9% within
the past 3 years.
DISCUSSION
Despite lower mortality from breast cancer at younger ages, the
issue of the effectiveness of screening below age 50 is an important
public health question in the UK, due to both demands from the
women concerned and the possible implications for the NHS.
Although cancer incidence in women in their 40s is approximately
half that of women in their 50s, the proportion of all female deaths
due to breast cancer is higher in women in their 40s. A third of life-
years lost due to breast cancer occurs in women diagnosed with
breast cancer in their 40s.
The benefit of mammographic screening was established
principally from mortality data on women screened at age 50 or
older, and while comparable data in younger women are available
from some of the RCTs, none included sufficient numbers to
reliably estimate the mortality effect. The most recent overview of
the Swedish trials found a relative risk of 0.80 (95% CI 0.63, 1.01)
in women aged 40–49 at entry at a median of 15.8 years of follow-
up (Nystrom et al, 2002). This analysis excluded the Kopparberg
arm of the Two County Study. An earlier overview had found a
nonsignificant 13% reduction at an average of 9 years of follow-up,
the difference emerging after 8 years. A meta-analysis of all RCTs
including the Canadian NBSS1 trial found a reduction of 18% in
this age group (Hendrick et al, 1997). The Canadian NBSS1 trial,
which was designed to compare the effect of screening by
mammography and physical examination with an initial physical
examination only in women aged 40–49 at entry, has suffered from
low statistical power, and has also been criticised for the use of a
volunteer population and doubts about the quality of mammo-
graphy. After 11–16 years of follow-up, this trial has shown no
difference in breast cancer mortality between the two arms (Miller
et al, 2002).
Cancer detection rates in the current trial do not increase greatly
with age until the later screening rounds at ages 46 or more. Rates
of recall for assessment are lower, particularly at the first screen,
than for women aged 50–64 in the national programme, but the
lower cancer detection rate means that the positive predictive value
of recall is lower.
In the early years of the trial, concerns were raised about the
uptake of screening that could be achieved in this age group, and
about the extent of screening in the control arm, which would
dilute any observed effect. In the event, uptake of invitation has
remained satisfactory at around 70%, although it appears to fall
slightly in the final round(s). The ‘loss to screening’ due to women
moving is similar to that which has occurred in other trials, such as
the UK Trial of Early Detection of Breast Cancer (Moss et al, 1999).
Our estimates of the extent of screening in the control arm show
little evidence of regular mammography.
The current trial has used annual invitation for screening due to
concerns about lower sensitivity of mammography and possible
faster mean growth rate of tumours in this age group.
There are limited data available from other studies on cancer
detection rates in this age group, particularly at the lower end, and
most rates are for women aged 40–49. In the Gothenburg trial,
which included five rounds at intervals of 18 months, detection
rates in women aged 40–44 at entry were 0.07% at first screen, and
0.18 at subsequent screens.
The trial is set completely within the NHSBSP framework; while
this has caused some logistical problems where programmes have
had to balance the trial requirements with those of the national
programme, it should ensure the applicability of the results to the
UK programme.
Uptake in this trial is likely to be lower than would be seen if the
national programme were extended to this age group. There has
been no health promotion associated with the trial, in order to
avoid increasing demand for screening in the control arm. In
addition, women who have moved to centres not participating in
the trial will not have continued to be routinely invited for
screening.
Table 7 All-cause mortality excluding breast cancer, by year in trial (data up to 31 March 2002)
Control arm Intervention arm Total
Year in
trial
No. of
women
Woman-
years Deaths
Rate per
1000 w
years
No. of
women
Woman-
years Deaths
Rate per
1000 w
years
No. of
women
Woman-
years Deaths
Rate per
1000 w
years
1 106971 106908 86 0.80 53890 53862 42 0.78 160861 160770 128 0.80
2 106871 106824 107 1.00 53847 53822 61 1.13 160718 160646 168 1.05
3 106746 106669 121 1.13 53777 53739 61 1.14 160523 160408 182 1.13
4 106609 106538 137 1.29 53711 53669 82 1.53 160320 160207 219 1.37
5 106449 106346 138 1.30 53623 53574 73 1.36 160072 159920 211 1.32
6 106276 104648 152 1.45 53533 52698 79 1.50 159809 157346 231 1.47
7 100386 92599 137 1.48 50539 46660 68 1.46 150925 139259 205 1.47
8 84076 69840 116 1.66 42398 35188 62 1.76 126474 105028 178 1.69
9 54314 42284 77 1.82 27326 21252 36 1.69 81640 63536 113 1.78
10 30375 16539 42 2.54 15278 8343 15 1.80 45653 24882 57 2.29
11 7470 4245 4 0.94 3739 2011 5 2.49 11209 6256 9 1.44
Total 863440 1117 1.29 434818 584 1.34 1298258 1701 1.31
Table 6 Interval cancers and estimate of sensitivity (data up to 31
December 1999)
Interval cancers
within 12
months (O)
Expected
cancers (E) Sensitivity
a (%)
1st screen 13 49.4 73.6
2nd and 3rd screen 47 88.4 46.8
4th and 5th screen 28 68.1 58.9
Later screens 11 31.0 64.5
In situ and microinvasive cases excluded.
a(1 O/E) 100%.
Effectiveness of mammographic screening in women
S Moss et al
953
British Journal of Cancer (2005) 92(5), 949–954 & 2005 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yWhile fieldwork is continuing, there is likely to remain an excess
of breast cancers in the intervention arm due to advancement of
diagnosis. Screening data collection will continue until all women
have been invited for screening as part of the national programme,
by which time incidence rates would be expected to be equal in the
two arms; this will take until 2009. The trial was designed to
compare mortality from breast cancer at 10 years of follow-up.
This length of follow-up has now been achieved and a mortality
analysis will be conducted once it is decided that data ascertain-
ment is complete. Estimates of mortality reduction based on
pathology variables have been made (Moss et al, 2005), but
conclusions as to the effectiveness and cost-effectiveness of
screening in this age group must await definitive results on
mortality.
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